239 filings
Page 10 of 12
424B3
vs0uxn ky
22 Mar 17
Prospectus supplement
12:00am
10-K
pgj7berdtvze0iuvka
22 Mar 17
Annual report
12:00am
8-K
95t656gl5xfiql lp4
22 Mar 17
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
12:00am
424B3
p5lribn so
9 Mar 17
Prospectus supplement
12:00am
8-K/A
foogw
9 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K/A
p30 njd3jvp8pee
8 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
ks00pn1h2n4q6fea8z
8 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
nm4q9o5qb
17 Feb 17
Departure of Directors or Certain Officers
12:00am
424B3
gdc3gb61t
24 Jan 17
Prospectus supplement
12:00am
8-K
w8gaum
20 Jan 17
Other Events
12:00am
8-K
f81 06uoxnxzl
18 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
5qpgq4e z7rq1mvn
6 Jan 17
Departure of Directors or Certain Officers
12:00am
424B3
dhw15hw99
6 Dec 16
Prospectus supplement
12:00am
8-K
hpgjaqb5q1
6 Dec 16
Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
12:00am
424B3
f4mo nnmytrrcyzj5
5 Dec 16
Prospectus supplement
12:00am
8-K
uz0dsz7q4ikkcuv k9f
5 Dec 16
Other Events
12:00am
424B3
2q91dp kxwmyk6
21 Nov 16
Prospectus supplement
12:00am
8-K
i97lw9vqsbqh5r
21 Nov 16
Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
12:00am
424B3
cfgr4g m330tmw6ptmp
9 Nov 16
Prospectus supplement
12:00am
8-K
dqqq6us14rw2frsca7
9 Nov 16
Kadmon Provides Business Update and Reports Third Quarter 2016 Financial Results
12:00am